Ligand Pharmaceuticals
LGND
205 hedge funds and large institutions have $1.39B invested in Ligand Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 66 reducing their positions, and 23 closing their positions.
2,556% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $852K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
11.62% more ownership
Funds ownership: 141.45% → 153.07% (+12%)
4% more funds holding
Funds holding: 197 → 205 (+8)
4% more capital invested
Capital invested by funds: $1.33B → $1.39B (+$55.5M)
2% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 66
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$107M |
| 2 |
Man Group
London,
United Kingdom
|
+$9.59M |
| 3 |
Millennium Management
New York
|
+$8.18M |
| 4 |
Impax Asset Management Group
London,
United Kingdom
|
+$4.71M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.5M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$8.93M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$5.19M |
| 4 |
BlackRock
New York
|
-$3.7M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$3.58M |
LGND Hedge Fund Activity: Q3 2022 in Review
205 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2022, worth a combined $1.39B — up 4.2% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LGND positions and 23 closed out — a net gain of 10 holders — while 67 added to existing stakes and 66 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $107M. The largest seller was State Street, cutting an estimated $12.5M.
- 205 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2022, up from 197 in Q2 2022.
- Funds reported $1.39B of Ligand Pharmaceuticals stock for Q3 2022, up 4.2% quarter-over-quarter.
- 33 funds opened new Ligand Pharmaceuticals positions in Q3 2022 and 23 closed out, a net change of +10 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2022 was Janus Henderson Group, an estimated $107M added.
- The largest Ligand Pharmaceuticals seller in Q3 2022 was State Street, an estimated $12.5M sold.
Based on aggregated 13F filings for Q3 2022.